Author

Amit Mahipal

University Hospitals Seidman Cancer Center/Case Western Reserve University - Cited by 5,700 - Cancer

Biography

Dr. Mahipal is also involved in the development of novel therapeutic agents for gastrointestinal cancers. He is a member of Phase 1 clinical trial program at Mayo clinic and involved in drug development for oncology patients. He is the principal investigator for several early phase clinical trials including first-in-human studies. He has spearheaded several investigator initiated trials for pancreatic, liver and bile duct cancers.
Title
Cited by
Year
Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma
L Goyal, F Meric-Bernstam, A Hollebecque, JW Valle, C Morizane, ...New England Journal of Medicine 388 (3), 228-239, 2023202
43
2023
SWOG 1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers.
RT Shroff, KA Guthrie, AJ Scott, MJ Borad, LW Goff, K Matin, A Mahipal, ...Journal of Clinical Oncology 41 (4_suppl), LBA490-LBA490, 2023202
24
2023
Culture media composition influences patient-derived organoid ability to predict therapeutic responses in gastrointestinal cancers
TL Hogenson, H Xie, WJ Phillips, MD Toruner, JJ Li, IP Horn, DJ Kennedy, ...JCI insight 7 (22), 2022202
9
2022
Management of appendix neuroendocrine neoplasms: insights on the current guidelines
A Mohamed, S Wu, M Hamid, A Mahipal, S Cjakrabarti, D Bajor, ...Cancers 15 (1), 295, 2022202
4
2022
Why the Treatment Sequence Matters: Interplay Between Chemotherapy Cycles received, Cumulative dose Intensity, and Survival in Resected Early-Stage Pancreas Cancer
VS Wu, M Elshami, HJ Stitzel, JJ Lee, JJ Hue, RK Kyasaram, JM Hardacre, ...Annals of Surgery, 10.1097, 030
2
2023
Phase II study of FGFR1-3 inhibitor tinengotinib as monotherapy in patients with advanced or metastatic cholangiocarcinoma: Interim analysis.
MM Javle, C Fountzilas, D Li, LA Kankeu Fonkoua, J Fan, P Peng, ...Journal of Clinical Oncology 41 (4_suppl), 539-539, 030
2
2023
NEO-GAP: A single-arm, phase II feasibility trial of neoadjuvant gemcitabine, cisplatin, and nab-paclitaxel for resectable, high-risk intrahepatic cholangiocarcinoma
SK Maithel, JM Keilson, HST Cao, M Rupji, A Mahipal, BS Lin, MM Javle, ...Annals of Surgical Oncology, -9, 2023202
1
2023
Circulating tumor DNA-guided recurrence risk assessment in esophageal and gastric cancer: Assay holds the key
S Chakrabarti, A MahipalJCO Precision Oncology 7, e220070, 2023202
1
2023
A glimpse into the future of cholangiocarcinoma: Predicting the future incidence based on the current epidemiological data.
SH Tella, M Wieczorek, D Hodge, A MahipalJournal of Clinical Oncology 4 (4_suppl), 66-66, 2023202
1
2023
Outcome of receiving lenvatinib following immunotherapy in patients with advanced hepatocellular carcinoma.
J Gile, ME Palmer, MH Storandt, TS Bekaii-Saab, NH Tran, A MahipalJournal of Clinical Oncology 4 (4_suppl), 507-507, 2023202
1
2023

Referred From: https://scholar.google.com/citations?user=l-MSAucAAAAJ&hl=en

Cited by
Citations 5700
h-index 38
i10-index 100
Open Access Journals